(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Foreign journalist kidnapped in Iraq: Interior Ministry- National health ranking puts Georgia near bottom of list. Here's why
- Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again'
- Germany's Pistorius: NATO protects Europe from Iranian missiles
- Instructions to Upgrade the Security Elements of Your Kona SUV
- Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
